NASDAQ:ANAB AnaptysBio (ANAB) Stock Price, News & Analysis $48.73 +0.63 (+1.31%) Closing price 10/23/2026 04:00 PM EasternExtended Trading$48.44 -0.29 (-0.60%) As of 10/23/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About AnaptysBio Stock (NASDAQ:ANAB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get AnaptysBio alerts:Sign Up Key Stats Today's Range$47.05▼$48.8950-Day Range$45.43▼$59.6952-Week Range$20.18▼$72.36Volume468,091 shsAverage Volume582,829 shsMarket Capitalization$1.46 billionP/E Ratio9.07Dividend YieldN/APrice Target$77.79Consensus RatingModerate Buy Company Overview AnaptysBio, Inc. is a clinical-stage biotechnology company focused on developing antibody-based medicines for immune-mediated diseases. The company uses its proprietary antibody discovery and engineering platform to identify therapeutics designed to modulate immune-system pathways involved in inflammation and autoimmune disorders. AnaptysBio’s pipeline has included rosnilimab, an investigational antibody designed to activate the PD-1 immune checkpoint pathway, and imsidolimab, an investigational antibody targeting the interleukin-36 receptor. These programs have been evaluated in conditions including rheumatoid arthritis and inflammatory skin diseases. The company has also advanced additional immune-modulating antibody programs, including candidates targeting BTLA and other immune-regulatory mechanisms. Founded in 2005 and headquartered in San Diego, California, AnaptysBio has operated primarily as a research and development company and has pursued collaborations and licensing arrangements with larger pharmaceutical companies. Its programs are investigational, and the company’s drug candidates remain subject to clinical testing and regulatory review before they could be commercially available.AI Generated. May Contain Errors. Read More AnaptysBio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks79th Percentile Overall ScoreANAB MarketRank™: 3.95277069636 of 5 starsAnaptysBio scored higher than 79% of companies evaluated by MarketBeat, and ranked 112th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingAnaptysBio has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on no strong buy ratings, 13 buy ratings, 3 hold ratings, and 1 sell rating.Upside PotentialAnaptysBio has a consensus price target of $77.79, representing about 59.6% upside from its current price of $48.73.Amount of Analyst CoverageAnaptysBio has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about AnaptysBio's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for AnaptysBio are expected to grow in the coming year, from ($1.30) to $2.42 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AnaptysBio is 9.07, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.39.Price to Earnings Ratio vs. SectorThe P/E ratio of AnaptysBio is 9.07, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 271.33.Price to Book Value per Share RatioAnaptysBio has a P/B Ratio of 36.37. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about AnaptysBio's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted25.57% of the float of AnaptysBio has been sold short.Short Interest Ratio / Days to CoverAnaptysBio has a short interest ratio ("days to cover") of 8.19.Change versus previous monthShort interest in AnaptysBio has recently decreased by 3.70%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAnaptysBio does not currently pay a dividend.Dividend GrowthAnaptysBio does not have a long track record of dividend growth. News and Social Media2.6 / 5News Sentiment0.18 News SentimentAnaptysBio has a news sentiment score of 0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for AnaptysBio this week, compared to 5 articles on an average week.Search Interest3 people have searched for ANAB on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat Follows3 people have added AnaptysBio to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, AnaptysBio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $249,350.00 in company stock.Percentage Held by Insiders31.50% of the stock of AnaptysBio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsAnaptysBio has minimal institutional ownership at this time.Read more about AnaptysBio's insider trading history. Receive ANAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AnaptysBio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ANAB Stock News HeadlinesAnaptysBio quickly drops amid hearing on GSK/Tesaro contract breachOctober 20, 2026 | msn.comAnaptysBio Shares Gain on FDA Approval for Rectal Cancer DrugOctober 19, 2026 | marketscreener.comMWhy tech stocks are deadAI skeptics see dot-com era warning signs, and they have a point. But the real opportunity may not be in the big tech names pouring billions into data centers. Walmart's $24 million satellite network, AMR's Sabre system, and Capital One's 36,114 pricing tests all prove the same thing: compute has always been business's biggest moat, and it's about to get cheaper than ever. Porter Stansberry says one overlooked, government-protected sector is positioned to absorb this near-free compute boom and could become the next Magnificent 7.October 25 at 1:00 AM | Porter & Company (Ad)Jemperli (dostarlimab) Approved in the U.S. as First and Only Immunotherapy for Adults with MSI-H/dMMR Locally Advanced Rectal CancerOctober 19, 2026 | globenewswire.comAnaptysBio, Inc. (ANAB) - What Are Analysts Thinking About This Stock?October 18, 2026 | americanbankingnews.comAnaptysBio: Fully Valued; With Major Litigation UncertaintyOctober 13, 2026 | seekingalpha.comWhy this IPO stock, an AnaptysBio spinoff, just skyrocketed more than 25%October 12, 2026 | msn.comAnaptysBio (NASDAQ:ANAB) Director Sells 5,000 Shares of StockOctober 3, 2026 | insidertrades.comSee More Headlines ANAB Stock Analysis - Frequently Asked Questions How have ANAB shares performed this year? AnaptysBio's stock was trading at $48.48 at the beginning of the year. Since then, ANAB shares have increased by 0.5% and is now trading at $48.73. How were AnaptysBio's earnings last quarter? AnaptysBio, Inc. (NASDAQ:ANAB) posted its quarterly earnings results on Monday, September, 21st. The biotechnology company reported $5.11 earnings per share for the quarter, topping analysts' consensus estimates of ($0.47) by $5.58. The biotechnology company earned $27.49 million during the quarter, compared to the consensus estimate of $14.06 million. AnaptysBio had a trailing twelve-month return on equity of 112.00% and a net margin of 82.37%. Is AnaptysBio buying back stock? AnaptysBio's board initiated a stock buyback program on Friday, March 27th 2026, which permits the company to buy back $100,000,000 in outstanding shares, according to EventVestor. This means that the company could purchase up to 5.4% of its stock through open market purchases. Stock buyback programs are often an indication that the company's board of directors believes its stock is undervalued. When did AnaptysBio IPO? AnaptysBio (ANAB) raised $75 million in an initial public offering (IPO) on Thursday, January 26th 2017. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Credit Suisse and Stifel acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. Who are AnaptysBio's major shareholders? AnaptysBio's top institutional shareholders include Robeco Institutional Asset Management B.V. (0.06%), Farther Finance Advisors LLC (0.03%), Kings Path Partners LLC (0.01%) and State of Alaska Department of Revenue (0.01%). Insiders that own company stock include Ecor1 Capital, Llc, Daniel Faga, Paul F Lizzul, John P Schmid, Dennis Mulroy, Eric J Loumeau, Hollings Renton, Magda Marquet, J Anthony Ware and Dennis M Fenton. View institutional ownership trends. How do I buy shares of AnaptysBio? Shares of ANAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of AnaptysBio own? Based on aggregate information from My MarketBeat watchlists, some other companies that AnaptysBio investors own include NVIDIA (NVDA), Tesla (TSLA), Shopify (SHOP), Advanced Micro Devices (AMD), Salesforce (CRM), Broadcom (AVGO) and FuelCell Energy (FCEL). Company Calendar Last Earnings9/21/2026Today10/25/2026Next Earnings (Estimated)11/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2d) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 As of 2 days ago, ANAB's financial health entered the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ANAB CIK1370053 Webwww.anaptysbio.com Phone(858) 362-6295FaxN/AEmployees104Year Founded2005Price Target and Rating Average Price Target for AnaptysBio$77.79 High Price Target$100.00 Low Price Target$50.00 Potential Upside/Downside+59.6%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage17 Analysts Profitability EPS (Trailing Twelve Months)$5.37 Trailing P/E Ratio9.07 Forward P/E RatioN/A P/E GrowthN/ANet Income-$13.23 million Net Margins82.37% Pretax Margin-11.46% Return on Equity112.00% Return on Assets2.20% Debt Debt-to-Equity RatioN/A Current Ratio7.58 Quick Ratio7.58 Sales & Book Value Annual Sales$234.60 million Price / Sales6.21 Cash FlowN/A Price / Cash FlowN/A Book Value$1.34 per share Price / Book36.37Miscellaneous Outstanding Shares29,900,000Free Float20,478,000Market Cap$1.46 billion OptionableOptionable Beta0.76 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:ANAB) was last updated on 10/23/2026 by MarketBeat.com Staff. From Our PartnersThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | Sponsored$0. Later: $29.97.Bill Poulos is giving away his Simple Options Trading For Beginners book through a temporary link. Once that l...Profits Run | SponsoredThe $100 Stock Behind Elon's Next MoveA small, publicly traded supplier trading under $100 a share has reportedly worked alongside Elon Musk for mor...Paradigm Press | SponsoredEarth's biggest energy source: near Grand CanyonThe largest energy source on Earth contains 50,000 times every oil and gas reserve on the planet combined - an...Behind the Markets | SponsoredHe turned $12K into $1.65M without touching Apple or TeslaTim Sykes turned $12,415 in gift money into more than $1.65 million before graduating college, without trading...Tim Sykes | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredCigar Lake Flooded Again Uranium Supply Shock RepeatsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the 50 range to 136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AnaptysBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AnaptysBio With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.